Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Mark L. Warren, Meryl Brod, Jonas Håkan-Bloch, Thomas Sparre & Louis B. Chaykin. (2019) Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Current Medical Research and Opinion 35:9, pages 1623-1629.
Read now
Read now
Joan Schertz & Hilary Worton. (2018) Nurse evaluation of the redesigned fertility pen injector: a questionnaire-based observational survey. Expert Opinion on Drug Delivery 15:5, pages 435-442.
Read now
Read now
Barbara Domańska, Brenda VanLunen, Luke Peterson, Irina Mountian & Michael Schiff. (2017) Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis. Expert Opinion on Drug Delivery 14:1, pages 15-22.
Read now
Read now
Andreas Pfützner, Thomas Forst, Marcus Niemeyer & Timothy Bailey. (2014) Assessment for ease of use and preference of a new prefilled insulin pen (FlexTouch Degludec U100/U200) versus the SoloSTAR insulin pen by patients with diabetes and healthcare professionals. Expert Opinion on Drug Delivery 11:9, pages 1381-1389.
Read now
Read now
Kalliopi Pafili & Nikolaos Papanas. (2014) The importance of patient compliance with insulin pens: how can a new user-friendly pen help?. Expert Opinion on Drug Delivery 11:5, pages 629-632.
Read now
Read now
Dorte Götzche, Bo Ølgaard Rasmussen, Michael Torben Pedersen, Thomas Sparre, Ditlef Bucher & Marcus Niemeyer. (2013) Injection force and dose accuracy of FlexTouch for the delivery of a new basal insulin. Expert Opinion on Drug Delivery 10:12, pages 1613-1619.
Read now
Read now
Rosemarie Lajara, German Guerrero & Jerome Thurman. (2012) Healthcare professional and patient perceptions of a new prefilled insulin pen versus vial and syringe. Expert Opinion on Drug Delivery 9:10, pages 1181-1196.
Read now
Read now
David Oyer, Marcus Niemeyer & Alan Moses. (2012) Empowering People with Diabetes: Improving Perceptions and Outcomes with Technical Advances in Insulin Pens. Postgraduate Medicine 124:5, pages 110-120.
Read now
Read now
Carlos Campos, Rosemarie Lajara & Tony Deluzio. (2012) Usability and preference assessment of a new prefilled insulin pen versus vial and syringe in people with diabetes, physicians and nurses. Expert Opinion on Pharmacotherapy 13:13, pages 1837-1846.
Read now
Read now
Articles from other publishers (12)
Małgorzata Masierek, Katarzyna Nabrdalik, Oliwia Janota, Hanna Kwiendacz, Maksymilian Macherski & Janusz Gumprecht. (2022) The Review of Insulin Pens—Past, Present, and Look to the Future. Frontiers in Endocrinology 13.
Crossref
Crossref
Arvind GuptaSanjeev PhatakY. Sadashiv RaoJayanthy Ramesh & Debmalya Sanyal. (2020) Consensus on Choice of Insulin Pen Devices in Routine Clinical Practice in India. Diabetes Technology & Therapeutics 22:10, pages 777-786.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Karin S. Coyne, Paula K. Wullenweber, Katelyn N. Cutts, Jessica B. Jordan, Qianqian Wang, Maria Yu, Brooke M. Currie, Karen G. Malley, K. Jack Ishak, Ryan T. Hietpas & Luis‐Emilio García‐Pérez. (2019) Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism 22:3, pages 355-364.
Crossref
Crossref
Eric Zijlstra, Hans‐Veit Coester, Tim Heise, Leona Plum‐Mörschel, Ole Rasmussen, Tord Rikte, Line Kynemund Pedersen, Marianne Qvist & Thomas Sparre. (2018) Injecting without pressing a button: An exploratory study of a shield‐triggered injection mechanism. Diabetes, Obesity and Metabolism 20:5, pages 1140-1147.
Crossref
Crossref
Louis S. Matza, Kristina S. Boye, Katie D. Stewart, Evan W. Davies & Rosirene Paczkowski. (2017) Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Services Research 17:1.
Crossref
Crossref
Niels GudiksenThibaud HofstätterBirgitte B. RønnThomas Sparre. (2017) FlexTouch: An Insulin Pen-Injector with a Low Activation Force Across Different Insulin Formulations, Needle Technologies, and Temperature Conditions. Diabetes Technology & Therapeutics 19:10, pages 603-607.
Crossref
Crossref
Anna Rydén, Stephanie Chen, Emuella Flood, Beverly Romero & Susan Grandy. (2017) Discrete Choice Experiment Attribute Selection Using a Multinational Interview Study: Treatment Features Important to Patients with Type 2 Diabetes Mellitus. The Patient - Patient-Centered Outcomes Research 10:4, pages 475-487.
Crossref
Crossref
Colin H. Ridyard, Dalia M. M. Dawoud, Lorna V. Tuersley & Dyfrig A. Hughes. (2016) A Systematic Review of Patients’ Perspectives on the Subcutaneous Route of Medication Administration. The Patient - Patient-Centered Outcomes Research 9:4, pages 281-292.
Crossref
Crossref
Ken Fujioka, Thomas Sparre, Lily Yong-Hui Sun, Susanne Krogsgaard & Robert F. Kushner. (2015) Usability of the Novel Liraglutide 3.0 mg Pen Injector Among Overweight or Obese Adult Patients With or Without Prior Injection Experience. Journal of Diabetes Science and Technology 10:1, pages 164-174.
Crossref
Crossref
Glenn Matfin, Kate Van Brunt, Alan G. Zimmermann, Rebecca Threlkeld & Debra A. Ignaut. (2015) Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes. Journal of Diabetes Science and Technology 9:5, pages 1071-1079.
Crossref
Crossref
Bruce Bode, Louis Chaykin, Allen Sussman, Mark Warren, Marcus Niemeyer, Rasmus Rabøl & Helena Rodbard. (2014) Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare). Endocrine Practice 20:8, pages 785-791.
Crossref
Crossref
Athena Philis-Tsimikas, Meryl Brod, Marcus Niemeyer, Ann Marie Ocampo Francisco & Jeffrey Rothman. (2013) Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use). Advances in Therapy 30:6, pages 607-622.
Crossref
Crossref